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Abstract Most genes are members of a family. It is generally
believed that a gene family derives from an ancestral gene by
duplication and divergence. The tumor suppressor p53 was a
striking exception to this established rule. However, two new p53
homologs, p63 and p73, have recently been described [1^6]. At
the sequence level, p63 and p73 are more similar to each other
than each is to p53, suggesting the possibility that the ancestral
gene is a gene resembling p63/p73, while p53 is phylogenetically
younger [1,2].
The complexity of the family has also been enriched by the
alternatively spliced forms of p63 and p73, which give rise to a
complex network of proteins involved in the control of cell
proliferation, apoptosis and development [1,2,4,7^9].
In this review we will mainly focus on similarities and differences
as well as relationships among p63, p73 and p53. ß 2001 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Genomic organization of p53 family members
The genomic organization of the p53 gene is highly con-
served among di¡erent species. The human p53 gene is ap-
proximately 20 kb and contains 11 exons [10]. The p73 and
p63 genes are approximately 65 kb and contain 14 and 15
exons, respectively [1,2]. The p53 family members share a
large ¢rst intron that is 10.7 kb in p53 and close to 32 kb
in p73 and p63 [11]. In p53, as well as in p73, exon 1 is non-
coding and the mRNA derived from this exon might in£uence
translation [12]. Thus, p53, p73 and probably p63 show a high
similarity in the exon/intron organization (Fig. 1A).
The human p73 promoter has recently been characterized
[13]. It has a TATA-like box and displays a low homology to
the p53 promoter [14]. Partial characterization of a large re-
gion upstream of the start site of exon 1 has revealed the
presence of three E2F sites which may account for the recent
¢nding that p73 expression is triggered, at the transcriptional
level, by E2F-1 overexpression [13,15,16] (Fig. 1B). The puta-
tive ATG for the p73 variants is located in exon 2. Interest-
ingly, a 1 kb fragment in the large intron upstream of the
ATG functions as a silencer suggesting that regulatory ele-
ments located in this region may contribute to a tight regu-
lation of p73 expression in di¡erent tissues or in response to
di¡erent stimuli (Fontemaggi and Blandino, unpublished ob-
servations) (Fig. 1B). At present, too little is known about the
transcriptional regulation of p53 family members to allow
¢rm conclusions. Further characterization of the promoter
regions of p73 and p63 will tell us whether the three genes
of the family also share common regulatory elements.
2. Structure of p53 family members
Human p53 is translated from a single mRNA with a single
open reading frame. It comprises 393 amino acid residues and
includes three main functional domains: an N-terminal trans-
activation domain (TAD), a central DNA binding core do-
main (DBD) and a C-terminal oligomerization domain (OLD)
[17^20]. The integrity of the above mentioned domains is
strictly required for the e⁄cient binding of p53 to recognition
sites of target genes as well as for transcriptional activation
[17]. Unlike p53, the p63 and p73 genes encode several poly-
peptides (Fig. 2). Three p63 isoforms, K, L and Q, are trans-
lated from RNA molecules that share a common 5P end and
di¡er at their 3P end because of alternative splicings [2,4].
Three N-terminal deleted p63 isoforms are generated by a
second internal promoter located upstream of exon 3 [2]. In-
terestingly, these deleted isoforms lose the ability to transacti-
vate target genes and may function as dominant negative of
either p63 isoforms or p53 [2]. Two p73 polypeptides were
originally identi¢ed. The longer one, named p73K, comprises
636 amino acids. The shorter one, named p73L, lacks the C-
terminal tail and derives from an alternative splicing of exon
13 [1]. The amino acid sequence of p73L coincides with the
494 amino-terminal residues of p73K with the addition of a
short carboxy-terminal tail of ¢ve residues. Four additional
p73 spliced variants have recently been identi¢ed [7^9]. Fur-
thermore, an isoform of mouse p73 truncated in the N-termi-
nus has recently been found and shown to prevent apoptosis
in sympathetic neurons after nerve growth factor withdrawal
or p53 overexpression [21].
The p63 and p73 proteins display a high homology to p53.
The most prominent degree of homology with p53 is found in
the DBD (63%) [1]. Furthermore, the critical residues for the
proper folding of the entire domain, as well as for the binding
to the target DNA sequences, are strictly conserved [1,19]. A
lower, but still signi¢cant degree of homology to p53 occurs at
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Fig. 1. Genomic organization of p63, p73 and p53. Exon/intron organization of p63, p73 and p53 with their relative isoforms. The sizes of in-
trons and exons are not drawn to scale (A). The promoter region of p63 has not been cloned yet. All genes present a large intron 1 and the
ATG is in exon 2. The region upstream of exon 1 is di¡erently organized between p53 and p73 (B). In p73 the positions are relative to the ¢rst
nucleotide of the published p73 cDNA [1]. In p53 the positions are relative to the major start site for transcription.
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TAD (22^29%) and OLD (42%) of p63 and p73 [22]. The
three-dimensional structure of the C-terminal tail of p73 has
recently been solved by nuclear magnetic resonance spectros-
copy. It consists of a ¢ve-helix bundle (487^554 residues)
characterized by a marked similarity to the structure of sterile
K motif (SAM) domains [23]. These domains are shown to be
protein^protein interaction modules present in several cyto-
plasmic signaling proteins and in transcription factors
[24,25]. For instance, SAM-mediated dimerization has been
proposed to contribute to Eph receptor activation and self-
association of ETS transcription factors. However, by using
di¡erent approaches, Arrowsmith’s group has recently re-
ported that the p73 SAM domain does not homo-oligomerize
[23]. Thus, further evidence needs to be collected in order to
establish whether the SAM domain modulates p73 and per-
haps p63 functions, by either interacting directly with target
proteins or modifying the C-terminal tail.
3. Regulation of p53 family members
It has been found that several stress signals strongly and
rapidly activate p53. Due to its biological outcomes, including
apoptotic death, p53 activity needs to be tightly controlled.
Several studies have clearly reported that p53 protein levels
increase swiftly in response to DNA damage and to other
types of stress, mainly through a signi¢cant increase in the
protein half-life [26^28]. It has recently been reported that
MDM2 is a key player in the regulation of p53 stability.
MDM2, the product of a p53-inducible gene, binds to and
suppresses p53 activity by promoting its proteolytic degrada-
tion [29^32]. p53 induces the expression of MDM2 that, in
turn, controls p53 activity and stability, giving rise to an au-
toregulatory feedback loop. Mdm2 de¢cient mice are early
lethal but the simultaneous deletion of p53 rescues this phe-
notype, indicating that the MDM2-mediated control of p53
activities is crucial for proper development [33,34]. Interfer-
ence with the binding of MDM2 to p53 by monoclonal anti-
bodies or competitor peptides causes stabilization and accu-
mulation of p53 even in unstressed cells [35]. On the other
hand, tumor cells carrying mutant forms of p53 are believed
to have elevated levels of p53 protein because of their inability
to increase Mdm2 gene expression, with consequent impair-
ment of MDM2-mediated degradation of p53 [36,37]. Recent
studies have shed light on the mechanism by which MDM2
promotes p53 degradation. MDM2 itself shows a speci¢c E3
ubiquitin ligase activity, which is su⁄cient to covalently at-
tach ubiquitin groups to p53 as well as to itself [38^40]. Nu-
cleo-cytoplasmic shuttling of MDM2 is important in promot-
ing p53 degradation e⁄ciently [41^44]. It has been proposed
that MDM2 may be responsible for translocating p53 into the
cytoplasm where degradation takes place. However, a nuclear
export signal for p53 has recently been identi¢ed [45]. These
¢ndings indicate that MDM2 and p53 may exit from the
nucleus independently. In contrast, no nuclear export signals
have been identi¢ed in p63 and p73 proteins.
p73 was shown to up-regulate at the transcriptional level
the expression of MDM2 that, in turn, reduces p73-dependent
transcription in di¡erent reporter assays [46]. These ¢ndings
suggest the existence of a p73/MDM2 regulatory loop similar
to the p53/MDM2 loop. However MDM2, by binding to
p73K and L, reduces their transcriptional activity but does
not induce their degradation [47,48]. Furthermore, in contrast
to p53, MDM2 binding promotes stability of p73K and L [49].
Thus, at least with respect to MDM2-mediated degradation,
p53 and p73 are clearly divergent.
An additional level of regulation of p53 and p73 is medi-
Fig. 2. The protein structure of the di¡erent isoforms of the three family members is shown. The major functional implications, according to
the knockout mice, are schematically represented by the neuronal cell for p73 and the epithelial cell for p63. The ubiquitous presence and the
stress-induced activation of p53 has been exempli¢ed by a generic cell. TAD: transactivation domain; DBD: DNA binding domain; OLD:
oligomerization domain; SAM: sterile K motif.
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ated by the covalent addition of SUMO-1 [50^52]. Unlike
p73, sumolation of p53 increases its transcriptional activity.
If this apparent discrepancy re£ects an additional divergence
in the regulation of p53 versus p73 needs to be explored by
further experiments.
4. Signals from DNA damage activate di¡erently p53, p73 and
p63
Over the past few years, many e¡orts have been focused on
understanding the mechanisms underlying p53 stabilization.
Many types of DNA damage that cause p53 stabilization
have been reported to induce phosphorylation of p53 at spe-
ci¢c sites [20,53]. Of particular interest are Ser15, Ser20, Ser37
and Thr18 of human p53, whose phosphorylation reduces the
association with MDM2 and consequently protects p53 from
degradation [54^58] (Fig. 3). A clear example of the chain of
events connecting DNA damage to p53 stabilization is pro-
vided by the ionizing radiation-activated ATM kinase that, by
phosphorylating p53 at Ser15 reduces its degradation by
MDM2 [59,60]. p53 stabilization can also be achieved by
phosphorylation of MDM2 that results in reduced association
with p53 [61].
Unlike p53, p73 was originally shown not to be induced in
response to UV irradiation [1]. Later on, it was reported that
cisplatin and ionizing radiation could regulate p73 through
protein accumulation or tyrosine phosphorylation, respec-
tively [62^64] (Fig. 3). These post-translational modi¢cations
of p73 occur through its physical interaction with the active
c-Abl kinase and promote the apoptotic activity of p73 [62^64].
Furthermore, p73 can also be acetylated by p300 upon treat-
ment with cisplatin (Costanzo and Levrero, personal commu-
nication). Taken together, these ¢ndings indicate that regula-
tion of p73 in response to di¡erent types of DNA damage is a
complex phenomenon that may be mediated by the recruit-
ment of di¡erent upstream proteins that modify p73.
By looking at the overall picture of covalent modi¢cations
of p53 family members in response to DNA damage, a strik-
ing divergence emerges between p53 and p73. Unlike p53, p73
stabilization seems only to be triggered by a subset of DNA
damaging agents. Moreover, the p73 response to stress was
found to be mediated by tyrosine phosphorylation while this
type of modi¢cation was never observed in p53 [63,64]. This
raises the question on what is the function of p73 tyrosine
phosphorylation in response to DNA damage. A simple ex-
planation would suggest that p73 recruits proteins that con-
tain SH2 domains [65]. This would imply that cells exposed to
DNA damage recruit a p73-dependent pathway distinct from
that activated by p53. For instance, the p73-dependent path-
way in response to DNA damage could preferentially be acti-
vated in cells that have an inactive p53 protein. Thus, signals
generated by DNA damage are integrated by either p53 or
p73 to induce speci¢c cellular responses that may also depend
on the speci¢c cellular context. Whether the third member of
the family, p63, is also involved in mechanisms underlying cell
responses to DNA damage needs to be thoroughly investi-
gated.
5. E2F-1-induced apoptosis by activation of p53 or p73
p53 can also be activated in response to oncogenes such as
Ras, Myc, E1A and L-catenin [66^69]. The molecular mecha-
nism underlying this stabilization has recently been elucidated
by the ¢nding that the deregulated overexpression of onco-
proteins causes accumulation of p14ARF, a small protein
encoded by the INK4a-ARF locus [70^72]. p14ARF interacts
with MDM2 in a region distinct from the binding domain of
p53 and promotes p53 stability through protection from
MDM2-mediated degradation [73^76]. Induction of p14ARF
is mainly at the transcriptional level and it can be ascribed to
E2F transcription factors [77]. Loss of physiological regula-
tion of E2F family is frequently found in human cancers,
indicating that deregulated activity of these transcription fac-
tors contributes to tumor development [78]. The importance
of the integrity of E2F activity in response to oncogenic stress
is made apparent by E2F-1-induced apoptosis [79]. Increasing
evidence indicates that E2F-1 can induce apoptosis in p53-
dependent and -independent ways [80]. Recent work by the
Vousden group has shown that exogenous expression of E2F-
1 sensitizes p53-null cells to the apoptosis induced by tumor
necrosis factor K through the inhibition of anti-apoptotic re-
sponses, as reported for activation of NF-kB [81]. An addi-
tional mechanism for E2F-1 induction of p53-independent ap-
optosis has recently been provided by reports that p73 is
induced at the transcriptional level by exogenous E2F-1 over-
expression in p53-null cells [15]. Induction of p73 by E2F-1 is
also triggered by T-cell receptor (TCR)-mediated apoptosis as
shown by the reduction of the apoptotic rate upon introduc-
tion of a p73 dominant negative [16]. Further support to the
functional link between E2F-1 and p73 emerges from the re-
sistance of primary T-cells derived from E2F-1 or p73 de¢-
cient mice to undergo TCR-mediated apoptosis [16]. Thus,
TCR-activated apoptosis is triggered by a speci¢c pathway
in which p73 is not recruited because of p53 absence or in-
activation but is the main downstream regulator of apoptosis.
6. p53 family members bind di¡erently to viral oncoproteins
p53 was originally discovered in 1979 as a protein that co-
precipitates with the large T antigen of SV40 [82,83] (Table 1).
Since this ¢rst observation, other viral oncoproteins such as
E6 of human papilloma virus and E1B 55 kDa of adenovirus
were reported to bind to and inactivate p53 [84,85]. Thus,
elimination of p53 activity is considered to be an essential
Fig. 3. Schematic representation of the feedback loop between p53/
MDM2 and p73/MDM2 in response to ionizing radiation (IR) and
cisplatin (CDDP). The biggest circles indicate protein stabilization.
FEBS 24569 14-2-01 Cyaan Magenta Geel Zwart
S. Strano et al./FEBS Letters 490 (2001) 163^170166
step for DNA tumor virus transformation [86]. In contrast,
none of the above mentioned viral oncoproteins binds or in-
activates p73 or p63 [87^89]. However, the possibility exists
that they can be bound and inactivated by other viral pro-
teins. Indeed, controversial data have been reported on the
ability of E4orf6 of adenovirus to inhibit p73 transcriptional
activity [89,90].
Adenovirus E1A promotes p53 stability through p14ARF-
mediated sequestration of MDM2 [68,91]. However, E1A can
also promote p53 degradation by binding to the transcription-
al coactivator protein p300/CBP. The latter associates with
the transactivation domain of p53, thereby causing Mdm2
gene transcription and consequently proteolytic degradation
of its product [92^94]. In addition, p300 interacts with both
p53 and MDM2 through domains distinct from those in-
volved in transcriptional coactivation [95]. Via these interac-
tions, p300 might allow the assembly of protein complexes
required for e⁄cient p53 degradation. Similar to p53, the
complex p300/CBP also binds to the N-terminus of p73 pro-
moting its transcriptional activity [89]. Whether acetylation of
p73 by p300/CBP, as shown for p53, results in a more e⁄cient
recognition of DNA target sequences and in a higher tran-
scriptional activity remains to be established.
7. Phenotypes of p533=3, p633=3 and p733=3 de¢cient mice
Clues to the physiological roles of p53, p63 and p73 came
from the respective knockout mice. The main phenotype of
the p53 de¢cient mouse is the high incidence of spontaneous
tumors, mainly sarcomas and lymphomas [96]. Together with
the fact that these mice are frequently viable, these ¢ndings
strongly indicate that p53 plays a pivotal role as a tumor
suppressor gene [96]. In contrast, p63 de¢cient mice are
born alive but show striking defects in development. Their
skin does not progress from the early stages of development,
lacking strati¢cation as well as expression of di¡erentiation
markers. The mammary glands, hair follicles and teeth are
absent in p633=3 mice [97,98]. In agreement with this pheno-
type, p63 was recently found mutated in patients with EEC
syndrome whose defects, ectrodactyly, ectodermal dysplasia
and facial clefts, closely resemble the phenotype of the
p633=3 mice [99].
p73 de¢cient mice exhibit severe defects, including hydro-
cephalus, hippocampal dysgenesis, chronic infections and in-
£ammation, and abnormalities in the pheromone sensory
pathway. However, they do not develop any spontaneous tu-
mors [100].
From the phenotypes described, a functional divergence
among p53, p63 and p73 clearly emerges. While p53 behaves
as a canonical tumor suppressor gene, both p63 and p73 play
a major role in ectodermal di¡erentiation and neurogenesis,
respectively. However, these ¢ndings do not exclude that each
member of the p53 family can exert some of the functions
ascribed speci¢cally to other members. This would explain
why inactivation of p53 interferes with muscle or hemato-
poietic di¡erentiation in vitro or Xenopus laevis development
in vivo and, alternatively, why p63 and p73 can recapitulate
p53-induced apoptosis as well as growth arrest [1,2,101^108].
Thus, the functions of p53 family members might overlap, at
least in speci¢c tissues, as a result of the requirement for
concerted and simultaneous activity of p53, p63 and p73 at
speci¢c stages of development.
Fig. 4. Homo- and hetero-complexes among the di¡erent members of the p53 family and the mutant p53 in tumor and normal cells. The cells
were drawn without nuclei since it is not known whether these complexes are exclusively nuclear or they are also present in the cytoplasm.
Most of the data available so far on hetero-complexes are from in vitro studies or co-immunoprecipitation in tumor cell lines. Thus, it is possi-
ble that the picture is not so divergent between normal and tumor cells. The complexes with a mutant p53 are obvious exceptions to this
hypothesis.
Table 1
Proteins interacting with the p53 family members
p63 p73 p53
TAD+proline-rich:
MDM2 ? + +
p300/CBP 3 + +
E1B 55 kDa 3 3 +
TFIID ? ? +
TFIIH ? ? +
RP-A ? ? +
c-AbI ? + +
DBD:
SV40 T Ag 3 3 +
p53BP1 ? ? +
p53BP2 ? ? +
OLD+C-terminal:
E6 HPV 3 3 +
TBP ? ? +
XBP ? ? +
XPD ? ? +
CSB ? ? +
E4orf6 3 + +
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8. p53, p73 and p63 in human cancers
The p53 tumor suppressor gene is the most frequent target
for genetic alterations in human cancers [109]. The most prev-
alent type of p53 mutations consists of missense mutations,
often within the highly conserved DBD of the protein [18,20],
leading to loss of the wild-type activity. However, at variance
with other tumor suppressor genes, cells bearing p53 muta-
tions typically maintain the expression of full-length protein.
This may suggest that, at least certain mutant forms of p53
can actively contribute to cancer progression through ‘gain of
function’ oncogenic activity. Such activity might depend on
the speci¢c p53 mutation and on the cell context in which the
biological outcome of the gain of function is evaluated [110].
We and others have previously reported that conformational
mutants such as p53His175, but not DNA contact mutants,
can increase cellular resistance to etoposide or contribute to
genomic instability by abrogating the mitotic spindle check-
point and consequently facilitating the generation of aneu-
ploid cells [111^114]. The molecular mechanisms underlying
the gain of function activities of mutant p53 remain to be
elucidated. We can delineate two mechanisms through which
mutant p53 exerts gain of function activities. The ¢rst one
relies on the assumption that mutant p53 can bind to DNA
through the association with DNA binding proteins and acti-
vate speci¢c target genes using its functional TAD [115]. In
support of this mechanism, it has been reported that human
tumor-derived p53, whose TAD was inactivated by site-di-
rected mutagenesis, lost the ability to increase tumorigenicity
in vitro and in vivo [116]. In a second scenario, mutant p53
binds to and sequesters proteins whose function is required
for anti-tumor functions such as apoptosis or growth inhibi-
tion. Interestingly, it has been reported that human tumor-
derived p53 mutants can associate with p73K and interfere
with its transcriptional activity and ability to induce apoptosis
when co-expressed in transient transfection assays [117]. Fur-
ther studies have demonstrated that the association between
mutant p53 and p73 occurs under physiological conditions as
indicated by co-immunoprecipitation from various tumor cells
[118,119]. Of note, di¡erent p73 variants exist in the cells,
giving rise to a family of proteins that adds a new level of
complexity to the understanding of p73 signaling in cancer
cells [1,7,8]. Recent ¢ndings indicate that mutant p53 can
also be engaged in physical interactions with di¡erent iso-
forms of p73 [119]. The Kaelin group has recently shown
that the association between human tumor-derived p53 mu-
tants and p73 is governed by a common polymorphism at
codon 72 of p53 that encodes Arg or Pro. Thus, both the
type of p53 mutation and the polymorphism at codon 72
in£uence whether mutant p53 interferes with p73 activity
[118]. Heterodimers between mutant p53 and p63 have re-
cently been shown to form in vitro and exist in tumor cells
([118] and Strano and Blandino, unpublished observations),
while further evidence needs to be collected to verify whether
a triple complex (mt-p53/p63/p73) can assemble in cancer
cells. In that case, cancer cells carrying mutant p53 will pro-
vide the ¢rst and clear example of a context in which p53
family members interact with one another. It will be of inter-
est to verify whether interactions occurring among the p53
family members impact on the chemoresistance of tumor cells
(Fig. 4).
While the DBD is the major site of mutations in p53, very
rare mutations in p73 and p63 have been found so far despite
extensive e¡orts [120^123]. Interestingly, the DBD of mutant
p53 is su⁄cient for the association with p73 isoforms [119].
The DBDs of mutant p53 proteins have been regarded as
‘dead’ domains since they cannot bind and activate p53 target
genes. However, these DBDs acquire a protein^protein inter-
action capacity that might contribute to the gain of function
activities of mutant p53 by sequestering and inactivating pro-
teins required for anti-tumor functions.
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